Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice

Breast Cancer Research

Volumn 9, Issue 4, 2007, Pages

  Calogero, Raffaele A ^a   Cordero, Francesca ^a   Forni, Guido ^a   Cavallo, Federica ^a  

^a Molecular Biotechnology Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CELL TRANSFORMATION; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; INFLAMMATION; MOUSE; PATHOLOGY; PROTO ONCOGENE; REVIEW; TRANSGENIC MOUSE; UDDER;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENES, ERBB-2; INFLAMMATION; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC;

EID: 40349102194     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1745     Document Type: Review

References (44)

1. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749-759. 10.1038/nri1703, 16175180.
2. Nauts HC, McLaren JR. Coley toxins: the first century. Adv Exp Med Biol 1990, 267:483-500.
3. Weinstein AJ, Gazdar AF, Sims HL, Levy HB. Lack of correlation between interferon induction and antitumour effect of poly I-poly C. Nat New Biol 1971, 231:53-54. 10.1038/231053a0, 5283388.
4. Krieg AM. CpG motifs: the active ingredient in bacterial extracts?. Nat Med 2003, 9:831-835. 10.1038/nm0703-831, 12835699.
5. Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006, 6:6.
6. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105-2116.
7. Cortesina G, De Stefani A, Galeazzi E, Cavallo GP, Badellino F, Margarino G, Jemma C, Forni G. Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer 1994, 69:572-576.
8. Forni G, Santoni A, Frati L. Cytokine-Induced Tumor Immunogenicity 1994, London, UK: Academic Press.
9. Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G. Role of neutrophils and CD4+T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992, 149:3627-3635.
10. Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo MP, Lollini PL, Forni G. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today 1997, 18:32-36. 10.1016/S0167-5699(97)80012-6, 9018972.
11. Di Carlo E, Modesti A, Coletti A, Colombo MP, Giovarelli M, Forni G, Diodoro MG, Musiani P. Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour. J Pathol 1998, 186:390-397. 10.1002/(SICI)1096-9896(199812)186:4<390::AID-PATH194>3.0.CO;2-Z, 10209488.
12. Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, Colombo MP, Forni G. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997, 89:1049-1058. 9230887, 10.1093/jnci/89.14.1049.
13. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994, 54:6022-6026.
14. Ferrantini M, Giovarelli M, Modesti A, Musiani P, Modica A, Venditti M, Peretti E, Lollini PL, Nanni P, Forni G. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J Immunol 1994, 153:4604-4615.
15. Giovarelli M, Cappello P, Forni G, Salcedo T, Moore PA, LeFleur DW, Nardelli B, Carlo ED, Lollini PL, Ruben S, et al. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol 2000, 164:3200-3206.
16. Forni G, Giovarelli M, Santoni A. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. J Immunol 1985, 134:1305-1311.
17. Bosco M, Giovarelli M, Forni M, Modesti A, Scarpa S, Masuelli L, Forni G. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently non-immunogenic tumors and induce a tumor-specific immune memory. J Immunol 1990, 145:3136-3143.
18. Weinberg RA. The Biology of Cancer 2006, Oxford, UK: Garland Science.
19. Pannellini T, Forni G, Musiani P. Immunobiology of her-2/neu transgenic mice. Breast Disease 2004, 20:33-42.
20. Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F, Ria F. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006, 177:7626-7633.
21. Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P, Wei WZ, Cavallo F. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006, 66:7734-7740. 10.1158/0008-5472.CAN-06-1432, 16885376.
22. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003, 102:2138-2145. 10.1182/blood-2003-01-0190, 12750171.
23. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073, 11252954.
24. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998, 188:589-596. 10.1084/jem.188.3.589, 9687535.
25. Cifaldi L, Quaglino E, Di Carlo E, Musiani P, Spadaro M, Lollini PL, Wolf S, Boggio K, Forni G, Cavallo F. A light, nontoxic inter-leukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res 2001, 61:2809-2812.
26. Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, Amici A, Wei WZ, Musiani P, Lollini PL, et al. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 2005, 11:1941-1952. 10.1158/1078-0432.CCR-04-1873, 15756020.
27. Conti I, Dube C, Rollins BJ. Chemokine-based pathogenetic mechanisms in cancer. Novartis Found Symp 2004, 256:29-41. discussion 41-52..
28. Quaglino E, Rolla S, Iezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini PL, Lanzardo S, Forni G, Sanges R, et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 2004, 113:709-717. 351320, 14991069, 10.1172/JCI200419850.
29. Astolfi A, Landuzzi L, Nicoletti G, De Giovanni C, Croci S, Palladini A, Ferrini S, Iezzi M, Musiani P, Cavallo F, et al. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am J Pathol 2005, 166:1205-1216. 1602398, 15793299.
30. Astolfi A, Rolla S, Nanni P, Quaglino E, De Giovanni C, Iezzi M, Musiani P, Forni G, Lollini PL, Cavallo F, et al. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. Cancer Immunol Immunother 2005, 54:599-610. 10.1007/s00262-004-0635-4, 15690207.
31. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004, 64:2858-2864. 10.1158/0008-5472.CAN-03-2962, 15087404.
32. Cavallo F, Astolfi A, Iezzi M, Cordero F, Lollini PL, Forni G, Calogero R. An integrated approach of immunogenomics and bioinformatics to identify new tumor associated antigens (TAA) for mammary cancer immunological prevention. BMC Bioinformatics 2005, 6(Suppl 4):S7. 1866378, 16351756, 10.1186/1471-2105-6-S4-S7.
33. Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 2004, 20:3705-3706. 10.1093/bioinformatics/bth449, 15297296.
34. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:Article 3.
35. Westfall PH, Krishen A, Young SS. Using prior information to allocate significance levels for multiple endpoints. Stat Med 1998, 17:2107-2119. 10.1002/(SICI)1097-0258(19980930)17:18<2107::AID-SIM910>3.0.CO;2-W, 9789917.
36. Ingenuity Systems. , http://www.ingenuity.com
37. Hu P, Bader G, Wigle DA, Emili A. Computational prediction of cancer-gene function. Nat Rev Cancer 2007, 7:23-34. 10.1038/nrc2036, 17167517.
38. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541. 10.1016/j.ccr.2006.10.009, 17157792.
39. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 17157791.
40. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, Gabrielson E. A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res 2004, 10:2922-2927. 10.1158/1078-0432.CCR-03-0490, 15131026.
41. Cavallo F, Quaglino E, Cifaldi L, Di Carlo E, Andre A, Bernabei P, Musiani P, Forni G, Calogero RA. Interleukin 12-activated lymphocytes influence tumor genetic programs. Cancer Res 2001, 61:3518-3523.
42. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999, 5:828-831. 10.1038/10552, 10395330.
43. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003, 100:2645-2650. 151394, 12598651, 10.1073/pnas.0437939100.
44. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 2007, (35 Database):D26-D31. 1761442, 17148475, 10.1093/nar/gkl993.